Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 13/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370237 | 0.90 | NT5E (0.46) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843632 | 0.89 | NT5E (0.54) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843642 | 0.89 | CDK1 (0.56) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843693 | 0.88 | NT5E (0.55) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843544 | 0.88 | NT5E (0.55) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843638 | 0.88 | NT5E (0.55) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843617 | 0.88 | KDM4E (0.46) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843701 | 0.87 | CDK1 (0.46) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843654 | 0.87 | CDK1 (0.52) | CDK1CDK5NT5ETDP1KDM4E | |
| SCHEMBL22843545 | 0.86 | CDK1 (0.54) | CDK1CDK5NT5ENPC1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | CDK1 4327/4885CDK5 3403/4885NT5E 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.